ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 2799
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

About the episode

Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial. 

The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across 12 months. Patients were randomized in a 1:1 fashion, to receive either oral torsemide or oral furosemide. Results from the QoL suggest that among patients with HF, a routine strategy of prescribing torsemide versus furosemide did not meaningfully impact patient symptoms or quality of life over 12-month follow-up.


Interview Questions:
1. What is the background of this study? 
2. How do torsemide and furosemide differ in terms of their mechanisms of action?
3. What was the rationale behind this QoL study?
4. What is the study design and patient population?
5. What data are you presenting at HFA 23?
6. Based on the results, what are the key messages?
7. What are the remaining unanswered questions regarding the choice of loop diuretic?

Faculty Biographies

Stephen J Greene

Stephen J Greene

Assistant Professor, Advanced Heart Failure & Transplantation

Dr Stephen Greene is Assistant Professor in Advanced Heart Failure & Transplantation at The Duke University School of Medicine in Durham, North Carolina, US. 

Dr Greene is a cardiologist with a clinical and research interest in heart failure. His research interests are focused on strategies and therapies to improve outcomes and quality of life for patients with heart failure. This involves research through clinical trials and through examining data from real-world clinical practice.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.